Gene & Cell Therapy and Rare Diseases’ Research
We conduct extensive research into the rapidly evolving gene and cell therapy and rare diseases arena to empower clients to win. Our strategic insights identify key players and developments, tailored to support BioPharma partners across R&D, clinical, regulatory, and commercial endeavors.
The gene and cell therapy space has advanced rapidly, with new assets targeting therapeutic areas such as oncology, immunology, cardiovascular, CNS, and rare diseases. With multiple companies active and new approvals happening, it’s critical to get strategic insights, whether you are a BioPharma company or investor.
Our services include (amongst others):
For BioPharma clients:
- Market and competitor insights on R&D, clinical development and commercial activities
- Extensive congress coverage, supporting brand owners with up-to-date intelligence
- Landscape analysis strengthened by expert interviews
- BD&L support
For Investors:
- Due diligence research
- New opportunity identification
- Access to experts’ opinion through a combination of in-house expertise and conduct of bespoke interviews
We also invite you to join our LinkedIn Gene, Cell and RNA Therapy Strategy Network group – a hub for networking and information.
Want to better understand and succeed in this complex space? Let’s connect!
Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.
August 26, 2025
Obesity Weekly News – August 26th 2025
August 26, 2025
Endocrinology Weekly Update – August 26th 2025
August 26, 2025
Winning in AI Search: 12 Key Takeaways for Brand Owners in the Age of AI Search
August 25, 2025
Oncology Weekly News – August 25th 2025
August 25, 2025
Artificial Intelligence and Digital Health Weekly News – August 25th 2025
August 25, 2025
Hematology Weekly News – August 25th 2025
August 22, 2025
Public Health Weekly News – August 22nd 2025
August 22, 2025
Vaccines Weekly Update – August 22nd 2025
August 22, 2025
Respiratory Weekly News – August 22nd 2025
August 21, 2025